Coeptis Therapeutics Holdings, INC 10-K annual reports

Coeptis Therapeutics Holdings, Inc. reports a net loss of $12.28 million for 2025, driven by increased operating expenses, while strategically expanding its technology segment and pursuing a merger and spin-out of its biotech operations.

Coeptis Therapeutics Holdings, Inc. has filed an amendment to its 2024 Annual Report on Form 10-K to include its previously omitted Executive Compensation Clawback Policy, ensuring compliance with SEC and Nasdaq rules.

Coeptis Therapeutics Holdings, Inc. files its 2024 10-K, highlighting its focus on cell therapy technologies, strategic partnerships, and financial results.

Coeptis Therapeutics Holdings, Inc. has filed an amendment to its 2023 annual report to correct the classification of subscription receivables on its balance sheet.

Coeptis Therapeutics Holdings, Inc. released its 2023 annual report, highlighting continued development of its product pipeline and strategic partnerships, while also noting significant operating losses.

Coeptis Therapeutics Holdings, Inc. has filed an amended 10-K to restate its 2022 financials due to an error in accounting for a convertible promissory note.